Publications
- Effect of clinical parameters on second- and third-line erlotinib treatment of EGFR wild type patients with advanced NSCLC2019 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
- Komentář ke studii (Afatinib vs. erlotinib ve 2. linii léčby pacientů s pokročilým skvamózním karcinomem plic - studie LUX-Lung 8)2016 | First Faculty of Medicine
- Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer2023 | Third Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Klinická onkologie2023 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Pilsen
- Léčba pokročilého a metastazujícího nemalobuněčného karcinomu plic bez řídicích mutac í2023 | First Faculty of Medicine
- Chest pain2022 | First Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University
- Atezolizumab in the first-line treatment of non-small cell lung cancer - the IMpower110 trial2022 | First Faculty of Medicine
- Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study2021 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment2021 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer2021 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Central Library of Charles University
Loading network view...